The transfusion medicine community has been involved in COVID-19 research under many different facets, ranging from blood donation shortages and COVID-19 convalescent plasma (CCP) donor identification [1] to the provision of blood components and derivatives to COVID-19 patients [2] and identifying ABO proteins as risk factors for COVID-19 severity [3]. The gene discussed is ABO; the disease is COVID-19.